199 related articles for article (PubMed ID: 35499171)
1. Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis.
Abdool Karim SS; Baxter C; Abdool Karim Q
Antivir Ther; 2022 Apr; 27(2):13596535211067589. PubMed ID: 35499171
[TBL] [Abstract][Full Text] [Related]
2. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.
Glidden DV; Das M; Dunn DT; Ebrahimi R; Zhao Y; Stirrup OT; Baeten JM; Anderson PL
J Int AIDS Soc; 2021 May; 24(5):e25744. PubMed ID: 34021709
[TBL] [Abstract][Full Text] [Related]
3. PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.
Robles G; Sauermilch D; Gandhi M; Starks TJ
AIDS Behav; 2021 Apr; 25(4):1299-1305. PubMed ID: 33206262
[TBL] [Abstract][Full Text] [Related]
4. Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
D'Angelo AB; Westmoreland DA; Carneiro PB; Johnson J; Grov C
AIDS Patient Care STDS; 2021 Aug; 35(8):327-334. PubMed ID: 34375141
[TBL] [Abstract][Full Text] [Related]
5. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review.
Murewanhema G; Malisheni M; Takah NF
Pan Afr Med J; 2021; 38():308. PubMed ID: 34178226
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.
Zhang Y; Clarke W; Marzinke MA; Piwowar-Manning E; Beauchamp G; Breaud A; Hendrix CW; Cloherty GA; Emel L; Rose S; Hightow-Weidman L; Siegel M; Shoptaw S; Fields SD; Wheeler D; Eshleman SH
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438932
[TBL] [Abstract][Full Text] [Related]
8. An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate.
McGowan IM; Kunjara Na Ayudhya RP; Brand RM; Marzinke MA; Hendrix CW; Johnson S; Piper J; Holtz TH; Curlin ME; Chitwarakorn A; Raengsakulrach B; Doncel G; Schwartz JL; Rooney JF; Cranston RD
AIDS Res Hum Retroviruses; 2022 Apr; 38(4):279-287. PubMed ID: 34541872
[TBL] [Abstract][Full Text] [Related]
9. Lamivudine/Tenofovir Disoproxil Fumarate is an Appropriate PrEP Regimen.
Mujugira A; Baeten JM; Hodges-Mameletzis I; Haberer JE
Drugs; 2020 Dec; 80(18):1881-1888. PubMed ID: 33040323
[TBL] [Abstract][Full Text] [Related]
10. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.
Mugwanya KK; Baeten JM
Expert Opin Drug Saf; 2016; 15(2):265-73. PubMed ID: 26634852
[TBL] [Abstract][Full Text] [Related]
11. HIV Preexposure Prophylaxis: A Review.
Riddell J; Amico KR; Mayer KH
JAMA; 2018 Mar; 319(12):1261-1268. PubMed ID: 29584848
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
[TBL] [Abstract][Full Text] [Related]
13. Brief Report: HIV-1 Evolution in Breakthrough Infections in a Human Trial of Oral Pre-exposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate.
Ruone S; Paxton L; McLaurin T; Taylor A; Hanson D; Heneine W; Brooks JT; García-Lerma JG
J Acquir Immune Defic Syndr; 2016 Jun; 72(2):129-32. PubMed ID: 26689970
[TBL] [Abstract][Full Text] [Related]
14. Geographic Variation in Qualified Health Plan Coverage and Prior Authorization Requirements for HIV Preexposure Prophylaxis.
McManus KA; Fuller B; Killelea A; Strumpf A; Powers SD; Rogawski McQuade ET
JAMA Netw Open; 2023 Nov; 6(11):e2342781. PubMed ID: 37948076
[TBL] [Abstract][Full Text] [Related]
15. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
Krakower DS; Mayer KH
Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
[TBL] [Abstract][Full Text] [Related]
16. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C;
Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention.
Yap PK; Loo Xin GL; Tan YY; Chellian J; Gupta G; Liew YK; Collet T; Dua K; Chellappan DK
J Pharm Pharmacol; 2019 Sep; 71(9):1339-1352. PubMed ID: 31144296
[TBL] [Abstract][Full Text] [Related]
18. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
[TBL] [Abstract][Full Text] [Related]
19. Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?
Taramasso L; Riccardi N; Del Puente F; Bruzzone B; Ripamonti D; D'Ambrosio B; Viscoli C; Di Biagio A
AIDS Res Hum Retroviruses; 2018 Feb; 34(2):168-170. PubMed ID: 29166777
[TBL] [Abstract][Full Text] [Related]
20. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
Adams JL; Shelley K; Nicol MR
Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
